# EDGAR Filing Document

**Accession Number:** 0001133416
**File Stem:** 0001140361-26-013760
**Filing Date:** 2026-4
**Character Count:** 2243
**Document Hash:** d996d200c33d497bc5f6405bd0f2cff1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-013760.hdr.sgml**: 20260508

**ACCESSION NUMBER**: 0001140361-26-013760

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260408

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GALECTIN THERAPEUTICS INC
- **CENTRAL INDEX KEY:** 0001133416
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 043562325
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 4960 PEACHTREE INDUSTRIAL BOULEVARD
- **STREET 2:** SUITE 240
- **CITY:** NORCROSS
- **STATE:** GA
- **ZIP:** 30071
- **BUSINESS PHONE:** 678-620-3186

**MAIL ADDRESS:**
- **STREET 1:** 4960 PEACHTREE INDUSTRIAL BOULEVARD
- **STREET 2:** SUITE 240
- **CITY:** NORCROSS
- **STATE:** GA
- **ZIP:** 30071

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRO PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20010612

April 8, 2026

#### VIA EDGAR
Division of Corporation Finance

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **RE:** | **Galectin Therapeutics Inc.<br> Registration Statement on Form S-3<br> File No. 333-294782<br> Filed March 31, 2026** |

---

In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended (the "Securities Act"), Galectin Therapeutics Inc. (the "Registrant") hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to April 10, 2026 at 4:00 p.m., Eastern Time, or as soon as thereafter practicable. In making this acceleration request, the Registrant acknowledges that it is aware of its responsibilities under the Securities Act.

Please call Brian Lee of Dentons US LLP at (212) 768-6926 to confirm the effectiveness of the Registration Statement or with any questions.

---

| |
|:---|
| Very truly yours, |
| **GALECTIN THERAPEUTICS INC.** |
| */s/ Jack W. Callicutt* |
| Jack W. Callicutt |
| Chief Financial Officer |

---

<br> cc: Brian Lee, Dentons US LLP

------